MDACC Study No:2006-0066 ( NCT No: NCT00439556)
Title:Bortezomib (VelcadeŽ) and Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with Lymphoid Malignancies
Principal Investigator:Issa F. Khouri
Treatment Agent:Carmustine; Cytarabine; Etoposide; Melphalan; Rituximab; Velcade
Study Status:Closed
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of Velcade (bortezomib) that can be given with BEAM (carmustine, etoposide,
cytarabine and melphalan) and rituximab in patients with lymphoma who receive a
stem cell transplant.
Hide details for General InformationGeneral Information

Disease Group:Leukemia; Lymphoma
Phase of Study:Phase II
Treatment Agents:Carmustine
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:3-4 weeks in the hospital.
Supported By:N/A
Return Visit:Every 3 months for the first year, then every 6 months while the patient is on
Home Care:N/A

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Issa F. Khouri
Dept:Stem Cell Transplantation and Cellular Therapy
For Clinical Trial Enrollment:713-792-8750
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults